Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACHV, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| TOCOSOL Paclitaxel | Breast Neoplasm | Phase 3 · NCT00251095 | Terminated |
| Paclitaxel | Breast Neoplasm | Phase 3 · NCT00251095 | Terminated |
| Custirsen | Non-Small Cell Lung Cancer | Phase 3 · NCT01630733 | Completed |
| Custirsen Sodium | Castrate-Resistant Prostate Cancer | Phase 3 · NCT01083615 | Terminated |
| Cytisinicline | Vaping Cessation | Phase 3 · NCT07392125 | Not yet recruiting |
| isotonic, 0.9% sodium chloride | Castrate-Resistant Prostate Cancer | Phase 3 · NCT01083615 | Terminated |
| Paclitaxel Vitamin E-Based Emulsion (S-8 | Urologic Neoplasms | Phase 2 · NCT00034177 | Completed |
| Apatorsen (OGX-427) | Urologic Neoplasms | Phase 2 · NCT01454089 | Completed |
| Experimental Arm: TOCOSOL Paclitaxel | Urologic Neoplasms | Phase 2 · NCT00034177 | Completed |
| Moxifloxacin | Smoking Cessation | Phase 1 · NCT05566288 | Completed |
| Tenifatecan (SN2310) | Breast Neoplasms | Phase 1 · NCT00385177 | Completed |
Also used in these trials (approved or third-party drugs, not ACHV's own candidates): Cabazitaxel, Prednisone, Dexamethasone, Docetaxel Anhydrous, Abiraterone Acetate, Gemcitabine Hydrochloride, Cisplatin, Carboplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ACHV holds $189.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $8.9M/quarter from operations, an estimated runway of 64.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACHV files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| venBio Global Strategic Fund V, L.P. | 5%+ holder (13D) | 10,737,317 | 10.43% | 2026-04-15 |
| Logos Global Management LP | Institution (13G, 5%+) | 10,538,440 | 10.24% | 2026-05-11 |
| Paradigm BioCapital Advisors LP | Institution (13G, 5%+) | 9,903,712 | 9.62% | 2026-04-17 |
| Franklin Resources, Inc. | Institution (13G, 5%+) | 8,878,942 | 8.63% | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | Institution (13F) | 7,614,836 | 7.40% | 2026-06-30 |
| TPG GP A, LLC 10% owner |
Insider | 6,877,580 | 6.68% | 2026-04-17 |
| Frazier Life Sciences Public Fund, L.P. | 5%+ holder (13G) | 6,625,788 | 6.44% | 2026-04-17 |
| venBio Partners LLC | Institution (13F) | 5,914,720 | 5.75% | 2026-06-30 |
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 5,502,064 | 5.35% | 2026-06-30 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 5,502,064 | 5.35% | 2026-04-17 |
| Vivo Opportunity, LLC | 5%+ holder (13G) | 5,305,640 | 5.16% | 2026-07-06 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,271,391 | 5.12% | 2026-06-30 |
Share count 102,902,490 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-19 filed 2026-08-21 |
Stewart Richard Alistair |
Sale (S) | 20,626 | $8.49 | 208,249 |
| 2026-07-27 filed 2026-07-29 |
Waldman Reid Alexander |
Option award (A) | 16,700 | – | – |
| 2026-07-27 filed 2026-07-29 |
Farrow Jeffrey S |
Option award (A) | 25,000 | – | – |
| 2026-07-27 filed 2026-07-29 |
Farrow Jeffrey S |
Option award (A) | 16,700 | – | – |
| 2026-07-27 filed 2026-07-29 |
Stewart Richard Alistair |
Option award (A) | 25,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-06-20 | cytisinicline | NDA | +9% | — | — |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACHV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →